Month:

Nasdaq: NRSN Treating Neurodegenerative Disease on Multiple Fronts NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) is a late-stage clinical biotechnology company developing combination therapies for neurodegenerative diseases, with amyotrophic lateral sclerosis (ALS) as its lead indication. Chart Website LATEST NEWS NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones READ MORE 5 Reasons… Continue reading Brizy #15471

Nasdaq: GTBP Directing the Patient’s Own NK Cells to Kill Cancer Cells GT Biopharma, Inc. (Nasdaq: GTBP) is a clinical-stage immuno-oncology company developing TriKE (Tri-specific Killer Engager) drugs that direct a patient’s own natural killer (NK) cells to kill cancer cells. Chart Website LATEST NEWS GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted… Continue reading GTBP